

2025
Prior Authorization Criteria
For
1340 Individual Compliant Plans

abatacept (Orencia)

Drugs

Orencia Intravenous

Covered Uses

FDA approved indications. Must be prescribed by a rheumatologist. Must fail Kevzara, Simponi Aria, Renflexis, adalimumab, and Enbrel for shared indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by a rheumatologist

Coverage Duration

Up to 12 months

Other Criteria

Orencia is indicated to treat rheumatoid arthritis, JIA, and Psoriatic arthritis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

abiraterone (Zytiga)

Drugs

Abiraterone Acetate Oral Tablet 250 MG

Covered Uses

FDA approved indications

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Abiraterone is indicated to treat metastatic prostate cancer. It is taken orally along with prednisone daily. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

acetaminophen / oxycodone (Xartemis XR)

Drugs

Xartemis XR

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Medication will be approved through referrals when written by Oncology or pain management .

Coverage Duration

12 Months

Other Criteria

Xartemis is an abuse deterrent opioid formulation used for pain. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Drugs

Hadlima, Hadlima PushTouch

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Adalimumab is indicated for the treatment of confirmed rheumatoid arthritis (RA), plaque psoriasis (PP), Psoriatic Arthritis (PSA) Crohn's disease (CD), ulcerative colitis (UC), Hydradenitis suppurativa, uveitis. This is non-preferred for commercial, ACA, and Exchange. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Must be written by Rheumatology, Dermatology or Specialist trained in management of prescribed condition. Dosing for indication is the FDA approved dose, off label dosing for an indication is not covered. For RA Patient must fail adequate trial of MTX in combination with a DMARD If MTX contraindicated, must try combination of 2-nonbiologic DMARDS (3 month trial in past 6 months). For Ankylosing Spondylitis PT must fail MTX or sulfasalazine and 2 NSAIDS within past 6 months. For Plaque Psoriasis patient must fail MTX or Soriatane and topical therapy. For Psoriatic Arthritis Patient must fail adequate trial of MTX or LEF in past 6 months. Renflexis, Azathioprine, and 6 Mercaptopurine. For hidradenitis suppurativa must have moderate to severe disease and have failed recent trial 8 to 12 week trial in past month of oral clindamycin and rifampin or doxycycline/Minocycline, Infliximab, AND oral retinoid (acitretin or isotretinoin) unless contraindicated in the past 6 months. For Uveitis patient must fail 8-12 week trial of methotrexate

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be written by Rheumatology, Dermatology or Specialist trained in management of prescribed condition.

Coverage Duration

12 months

Other Criteria

afatinib (Gilotrif)

Drugs **Gilotrif**

Covered Uses

Patient must have NSCLC mutations consistent with FDA label. Test for T790M mutation if previously on a TKI inhibitor

Exclusion Criteria

Required Medical Information

Medical notes, previous treatment history and associated studies, including test for T790M mutation if previously on a TKI inhibitor

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Gilotrif is an oral tyrosine kinase inhibitor indicated to treat NSCLC with the genetic tumor markers of exon 19 deletion and exon 21 substitution. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

alectinib (Alecensa)

Drugs **Alecensa**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be an oncologist

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Alecensa is indicated to treat patients with ALK+ metastatic Non-Small cell lung cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician

alitretinoin (Panretin)

Drugs **Panretin**

Covered Uses

FDA approved indications. Failure of vinblastine.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Panretin is a retinoid indicated for Kaposi sarcoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

almotriptan (Axert)

Drugs

Almotriptan Malate

Covered Uses

FDA approved indications This medication requires failure of rizatriptan and sumatriptan prior to coverage.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Axert is a 5-HT_{1B/1D} agonist indicated for treatment of migraine headaches. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

ambrisentan (Letairis)

Drugs

Ambrisentan

Covered Uses

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization. Patient must have failed or have contraindication to sildenafil. Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral. Approved referrals will initially provide coverage for 12 weeks. Continuation of coverage will be determined by an improvement of an objective test of exercise (6 minute walk) from baseline. Follow-up documentation must be submitted for continuation of coverage. Patients who have had an initial positive response based the 12 week follow-up will be approved for an additional 6 months, and re-evaluation with documentation will be required every 6 months for continuation of coverage.

Exclusion Criteria

This medication is contraindicated in pregnancy, those of childbearing ability who are not using contraception.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Initial approval for 12 weeks. See "Covered Use" for continuation of coverage details.

Other Criteria

Letairis is an endothelin receptor antagonist used to treat WHO group 1 pulmonary arterial hypertension. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

anakinra (Kineret)

Drugs

Kineret Subcutaneous Solution Prefilled Syringe

Covered Uses

FDA approved indications. Patient must fail two anti-TNF biologics and Xeljanz.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

Kineret is a biologic agent indicated for treatment of rheumatoid arthritis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

aprepitant (Emend)

Drugs

Aprepitant Oral Capsule, **Emend Oral Suspension Reconstituted**

Covered Uses

FDA approved indications. Patient must have failed Zofran. A pre-packaged three-day course of this medication will be approved per each co-pay incidental to a chemotherapy treatment cycle.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Medication will be approved through referrals when written by Oncology

Coverage Duration

12 months

Other Criteria

Emend is used as part of a three day regimen for chemotherapy induced nausea and vomiting (CINV) of moderate to highly emetogenic Chemotherapy treatments, and Post-Operative Nausea and Vomiting. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

aripiprazole (Abilify)

Drugs

Abilify Maintena Intramuscular Prefilled Syringe

Covered Uses

FDA approved indications. Failure of oral aripiprazole and lurasidone.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Psychiatrist or Neurologist through referrals for new starts.

Coverage Duration

12 months

Other Criteria

Aripiprazole is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

asfotase alfa (Strensiq)

Drugs Strensiq

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Criteria for coverage as follows: Must meet ALL of the following criteria: 1. Member is diagnosed with any of the following: a. Perinatal/infantile-onset hypophosphatasia (HPP) b. Juvenile-onset hypophosphatasia (HPP) AND 2. Member's diagnosis of HPP is confirmed by or in consultation with an endocrinologist or a bone and mineral specialist. AND 3. Member has skeletal abnormalities indicative of HPP - documentation from the medical record must be provided. a. Note: Examples of skeletal abnormalities include chest wall deformities, hypomineralized skeleton, rickets, nonhealing fractures. AND 4. Member has an alkaline phosphatase (ALP) level below age-adjusted lower limit of normal, while off medications which can lower ALP such as anti-resorptives. AND 5. Member has a pyridoxal-5'-phosphate (PLP) level greater than two times laboratory's upper limit, while off vitamin supplementation (2 week washout) AND 6. Member has an ALPL genetic mutation - laboratory documentation must be provided. AND 7. Member has an onset of clinical signs and symptoms of HPP prior to 12 years of age - documentation from the medical record must be provided. STRENSIQ continued.. AND 8. Strensiq is prescribed by or in consultation with an endocrinologist or a bone and mineral specialist. AND 9. Dose does not exceed 6 mg/kg/week. Initial approval 6 months. Continuation of Strensiq meets definition of Medical Necessity for members when the following criteria are met: 1. Member has demonstrated an objective clinical improvement in symptoms following initiation of asfotase alfa - documentation from the medical record must be provided. This could include improvement in fracture healing, improved 6 minute walk time, improved bone density, reduction in baseline disability. AND 2. Strensiq is prescribed by or in consultation with an endocrinologist or a bone and mineral specialist 3. Dose does not exceed: a. Perinatal/infantile-onset HPP: 9 mg/kg/week b. Juvenile-onset HPP: 6 mg/kg/week

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Strensiq is an enzyme replacement therapy indicated for infantile or pediatric onset hypophosphatasia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

axitinib (Inlyta)

Drugs **Inlyta**

Covered Uses

Inlyta is an oral tyrosine kinase inhibitor indicated for advanced renal cell carcinoma.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

12 months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

aztreonam (Cayston)

Drugs **Cayston**

Covered Uses

FDA approved indications. Failure or intolerance to Tobramycin nebulized solution

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 Months

Other Criteria

Cayston is indicated for treatment of pulmonary pseudomonas in cystic fibrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

beclomethasone (Qvar)

Drugs

Qvar RediHaler Inhalation Aerosol Breath Activated 40 MCG/ACT, 80 MCG/ACT

Covered Uses

FDA approved indications. Must have failed Arnuity and Flovent for overlapping indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 Months

Other Criteria

QVAR is an inhaled corticosteroid indicated for asthma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Benefix

Drugs

Benefix Intravenous Kit

Covered Uses

Approval will be based on Diagnosis of Hemophilia B and history of Bleeding or joint effusions OR perioperative prophylaxis

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

bosentan (Tracleer)

Drugs

Bosentan

Covered Uses

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization. Patient must have failed or have contraindication to sildenafil, ambrisentan, and tadalafil. Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral. Approved referrals will initially provide coverage for 12 weeks. Continuation of coverage will be determined by an improvement of an objective test of exercise (6 minute walk) from baseline. Follow-up documentation must be submitted for continuation of coverage. Patients who have had an initial positive response based the 12 week follow-up will be approved for an additional 6 months, and re-evaluation with documentation will be required every 6 months for continuation of coverage.

Exclusion Criteria

This medication is contraindicated in pregnancy, those of childbearing ability who are not using contraception, those on glyburide or cyclosporine and in those with active liver disease.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Initial approval for 12 weeks. See "Covered Use" for continuation of coverage details.

Other Criteria

Tracleer is indicated for the treatment of Primary pulmonary arterial hypertension or pulmonary hypertension related to connective tissue disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

bosutinib (Bosulif)

Drugs

Bosulif Oral Tablet

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. AND Failure of imatinib.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Restricted to hematology/oncology

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Bosulif is indicated for treatment of Ph+ CML after failure of a first line tyrosine kinase inhibitor. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

C1 esterase inhibitor (Berinert)

Drugs **Berinert**

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Must not be taking medications that can exacerbate the frequency and/or severity of hereditary angioedema(HAE) attacks including estrogens and ACE inhibitors.

Required Medical Information

Must have C1INH deficiency demonstrated by labs (C1INH and C4 labs)

Age Restriction

Prescriber Restriction

Must be prescribed by an immunologist, allergist or hematologist

Coverage Duration

12 months

Other Criteria

BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

cabozantinib (Cometriq)

Drugs

Cometriq (100 MG Daily Dose) Oral Kit 80 & 20 MG, Cometriq (140 MG Daily Dose) Oral Kit 3 x 20 MG & 80 MG, Cometriq (60 MG Daily Dose)

Covered Uses

FDA approved indications.

Exclusion Criteria

Combination use with other tyrosine kinase inhibitors is excluded.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be a Hematologist/Oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Cometriq is indicated for treatment of metastatic medullary thyroid cancer Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

carglumic acid (Carbaglu)

Drugs

Carglumic Acid Oral Tablet Soluble

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

Carbaglu is indicated to treat NAGS deficiency. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

ceritinib (Zykadia)

Drugs

Zykadia Oral Tablet

Covered Uses

FDA approved indications. Must have progressed on Xalkori.

Exclusion Criteria

Not covered in combination with other tyrosine kinase inhibitors or EGRf inhibitors.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Zykadia is a TKI inhibitor indicated for metastatic NSCLC which is ALK (anaplastic lymphoma kinase) positive, it is indicated for patients who have failed/progressed on crizotinib (Xalkori) Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

cinacalcet hydrochloride (Sensipar)

Drugs

Cinacalcet HCl

Covered Uses

FDA approved indications. Patient is identified as having hypercalcemia associated with parathyroid carcinoma OR Patient is identified as having hyperparathyroidism secondary ESRD in patient with elevated PTH. Patient must have failed phosphate binders and active Vitamin-D therapy, iPTH must be >300 in dialysis patients. This information is sent to the Referrals Department.

Exclusion Criteria

Not for use in children, pregnancy, seizure disorder.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

This medication must be prescribed by Nephrology or Endocrinology or Oncology

Coverage Duration

12 months

Other Criteria

Sensipar is indicated to treat hyperparathyroidism that is secondary to renal insufficiency or hypercalcemia secondary to parathyroid carcinoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

clobazam (Onfi)

Drugs

Clobazam

Covered Uses

FDA approved indications. Failure of levetiracetam, topiramate ,and clonazepam.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Neurologist through referrals for new starts.

Coverage Duration

12 Months

Other Criteria

Onfi is a benzodiazepine indicated to treat seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

cobimetinib (Cotellic)

Drugs Cotellic

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Must be prescribed by Oncologist. Must be used in combination with Zelboraf.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Cotellic is indicated for treatment of BRAF+ metastatic or unresectable melanoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

crizotinib (Xalkori)

Drugs

Xalkori Oral Capsule

Covered Uses

FDA approved indications.

Exclusion Criteria

Not covered in combination with other tyrosine kinase inhibitors or EGRF inhibitors.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Xalkori is a TKI inhibitor for metastatic NSCLC which is ALK (anaplastic lymphoma kinase) positive, or ROS positive. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

dabrafenib (Tafinlar)

Drugs

Tafinlar Oral Capsule

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Patient must have BRAF V600E/K mutation

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by an oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Tafinlar is a BRAF inhibitor indicated to treat BRAF+ V600e/k mutation Stage IIIc-IV metastatic Melanoma and NSCLC. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

dalfampridine (Ampyra)

Drugs

Dalfampridine ER

Covered Uses

Diagnosis of multiple sclerosis AND patient is ambulatory.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Initial - 3 months. Renewal - 12 months.

Other Criteria

Ampyra is indicated to treat patients with multiple sclerosis who have walking disability. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

dasatinib (Sprycel)

Drugs

Dasatinib

Covered Uses

FDA approved indications AND failure of imatinib.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Sprycel is an oral antineoplastic agent used to treat Philadelphia Chromosome + CML and PH+ ALL. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

deferasirox (Exjade)

Drugs

Deferasirox Oral Tablet Soluble

Covered Uses

FDA approved indications Patient has failed or is intolerant to Deferoxamine.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Exjade is an oral medication used to treat iron overload typically in patients receiving chronic RBC transfusions. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

deferiprone (Ferriprox)

Drugs

Deferiprone

Covered Uses

FDA approved indications. Prescriber restricted to Oncologist/hematologist. Failure of deferasirox and Desferal.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber restricted to Oncologist/hematologist.

Coverage Duration

Up to 12 months

Other Criteria

Ferriprox is indicated to treat iron overload secondary to transfusion dependence. This medication is only on the Medicare and Exchange formularies. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

degarelix (Firmagon)

Drugs

Firmagon

Covered Uses

FDA approved indications. Limited to two per month.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Written by oncology or urology

Coverage Duration

12 months

Other Criteria

Firmagon is indicated to treat advanced prostate cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

denosumab (Prolia)

Drugs

Prolia Subcutaneous Solution Prefilled Syringe

Covered Uses

FDA approved indications Intolerance or contraindication to injectable bisphosphonate required for coverage of Prolia.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Prolia is a RANK-L ligand antagonist indicated for treatment of osteoporosis and prevention of osteoporosis for patients taking aromatase inhibitors. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

dextromethorphan / quinidine (Nuedexta)

Drugs **Nuedexta**

Covered Uses

FDA approved indications.

Exclusion Criteria

Not covered for off-label use

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be a neurologist.

Coverage Duration

Up to 12 months

Other Criteria

Nuedexta is indicated to treat pseudobulbar affect. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

dimethyl fumarate (Tecfidera)

Drugs

Dimethyl Fumarate Oral, Dimethyl Fumarate Starter Pack Oral

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Neurology

Coverage Duration

12 months

Other Criteria

Dimethyl fumarate is an oral CMT (disease modifying treatment) indicated to treat relapsing remitting multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

dornase alfa (Pulmozyme)

Drugs

Pulmozyme Inhalation Solution 2.5 MG/2.5ML

Covered Uses

FDA approved indications. Patient must have an FVC \geq 40% of predicted value and recurrent pulmonary infections.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by a pulmonologist.

Coverage Duration

Up to 12 months

Other Criteria

Pulmozyme is indicated to reduce pulmonary exacerbation in patients with cystic fibrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

doxepin (Silenor 3mg)

Drugs

Doxepin HCl Oral Tablet

Covered Uses

FDA approved indications. Failure of zolpidem, zaleplon, trazadone, temazepam

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Silenor is indicated for the treatment of insomnia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

doxepin topical product (Zonalon)

Drugs

Doxepin HCl External

Covered Uses

FDA approved indication. Approved only for short term use.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribed by a dermatologist.

Coverage Duration

Approved only for short term use.

Other Criteria

This medication is a topical tricyclic for indicated for short term treatment of pruritus in patients with atopic dermatitis.

dronedarone (Multaq)

Drugs **Multaq**

Covered Uses

FDA approved indications. Must have previously failed or have contraindication to both sotalol and amiodarone.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Multaq is indicated for treatment of atrial fibrillation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

elagolix (Orilissa)

Drugs **Orilissa**

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Orilissa is indicated for moderate to severe pain due to endometriosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. Failure of an NSAID and oral contraceptive/progestin for endometriosis.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

OB/GYN

Coverage Duration

6 months

Other Criteria

**Drugs
OriaHnn**

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. OriaHnn is indicated for treatment of heavy menstrual bleeding due to uterine fibroids. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. Failure of an NSAID and oral contraceptive/progestin for endometriosis.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

OB/GYN

Coverage Duration

24 months

Other Criteria

eltrombopag (Promacta)

Drugs

Promacta Oral Packet 12.5 MG, Promacta Oral Tablet

Covered Uses

FDA approved indications. Patient must have chronic ITP and bleed risk, with platelet count less than 30,000, and refractory to IVIG, corticosteroids or splenectomy.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

Promacta is indicated to treat ITP and thrombocytopenia secondary to HCV treatment. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

enasidenib (Idhifa)

Drugs **Idhifa**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be a Hematologist/Oncologist

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Idhifa is indicated for treatment of relapsed or refractory AML in patients with an IDH2 mutation as detected by an approved test Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

entrectinib (Rozlytrek)

Drugs

Rozlytrek Oral Capsule

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Rozlytrek is a kinase inhibitor indicated for solid tumors with NTRK-Fusions and ROS-1 mutated Non-Small Cell lung cancer. Medical history, studies, and appropriate confirmatory tests are reviewed in Referrals and if approved will notify pharmacy and the physician.

enzalutamide (Xtandi)

Drugs **Xtandi**

Covered Uses

FDA approved indications. Coverage will be based on failure of Abiraterone for overlapping indications (Metastatic Prostate Cancer and Castrate sensitive high risk non-metastatic cancer).

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by oncologist or urologist.

Coverage Duration

Covered for 6 months and continuation based on lack of disease progression.

Other Criteria

Xtandi is an androgen receptor blocker used for Castrate Resistant Prostate Cancer pre- and post-chemotherapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

epoetin alpha-epbx (Retacrit)

Drugs

Retacrit Injection Solution 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Pharmacy coverage criteria as follows: FDA approved indications. Patient must have adequate iron stores (ferritin greater than or equal to 100 ng/ml, transferrin saturation greater than 20%). Hemoglobin for initiation and maintenance must be compliant with current FDA labeling.

Exclusion Criteria

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

6 months

Other Criteria

ESAs are used to treat anemia related to Chronic Kidney Disease, Chemotherapy, Myelodysplastic Syndrome, Antiviral therapy. Prior authorization is required for pharmacy coverage of medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

Drugs
Aimovig

Covered Uses

Aimovig is a anti-CGRP antibody indicated for prophylaxis of Episodic and Chronic Migraines

Episodic MigrainesAimovig will be approved based upon all of the following criteria:(1) Diagnosis of episodic migraines with both of the following:(a) Less than 15 headache days per month(b) Patient has 4 to 14 migraine days per month-AND-(2) Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used:(a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol(e) Venlafaxine (Effexor/Effexor XR)AND (3) Medication will not be used in combination with an oral CGRP antagonist or inhibitorAuthorization will be issued for 6 months.

2. Reauthorization. Aimovig will be approved based on all of the following criteria:(1) Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity-AND-(2) Medication will not be used in combination with an oral CGRP Antagonist.Authorization will be issued for 12 months.

B. Chronic Migraines

1. Initial TherapyAimovig will be approved based upon all of the following criteria:(1) Diagnosis of chronic migraines with both of the following:(a) Greater than or equal to 15 headache days per month continued.(b) Greater than or equal to 8 migraine days per month-AND-Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used:(a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol(e) Venlafaxine (Effexor/Effexor XR)-AND-(3) Medication will not be used in combination with an oral CGRP antagonist Authorization will be issued for 6 months.

2. Reauthorization. Aimovig will be approved based on all of the following criteria:(1) Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity-AND-(2) Medication will not be used in combination with an oral CGRP Antagonist.Authorization will be issued for 12 months.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

6 to 12 months

Other Criteria

ergotamine (Ergomar)

Drugs **Ergomar**

Covered Uses

FDA approved indications Failure of two formulary 5HT- antagonists (triptans).

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Neurologist

Coverage Duration

12 months

Other Criteria

Ergomar is indicted for treatment of vascular headaches. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

erlotinib (Tarceva)

Drugs

Erlotinib HCl

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Tarceva is indicated to treat patients with metastatic non-small cell lung cancer who possess an EGFR mutation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

eslicarbazepine (Aptiom)

Drugs **Aptiom**

Covered Uses

FDA approved indications. Failure of Oxcarbazepine and carbamazepine.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by neurology for adjunctive treatment of seizures.

Coverage Duration

12 months

Other Criteria

Aptiom is an anti-convulsant indicated for adjunctive treatment of partial seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

estrogens, esterified (USP) (Menest)

Drugs

Menest Oral Tablet 0.3 MG, 0.625 MG, 1.25 MG

Covered Uses

Used for palliative treatment of breast cancer.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by an oncologist.

Coverage Duration

Up to 12 months

Other Criteria

Menest is only covered for palliative treatment of breast cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

etanercept (Enbrel)

Drugs

Enbrel Mini, Enbrel Subcutaneous Solution 25 MG/0.5ML, Enbrel Subcutaneous Solution Prefilled Syringe, Enbrel Subcutaneous Solution Reconstituted, Enbrel SureClick Subcutaneous Solution Auto-Injector

Covered Uses

Indicated for RA, JRA, PSA, and Plaque Psoriasis. See "Guidelines for Enbrel" form.

Exclusion Criteria

FDA labeled contraindications

Required Medical Information

Medical notes, previous treatment history and associated studies

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Rheumatology, Dermatology or Specialist trained in management of prescribed condition

Coverage Duration

Up to 12 months

Other Criteria

For RA, patient must fail adequate trial of MTX in combination with a DMARD. If MTX is contraindicated, must try combination of 2-nonbiologic DMARDS (3month trial in past 6 months). For Ankylosing Spondylitis, patient must fail MTX (3 month trial in past 6 months) or sulfasalazine and 2 NSAIDS within past 6 months. For Plaque Psoriasis, patient must fail MTX or Soriatane (3 month trial in past 6 months) and topical therapy. For Psoriatic Arthritis, patient must fail adequate trial of MTX or LEF (3 month trial in past 6 months).

everolimus (Afinitor)

Drugs

Everolimus Oral Tablet 2.5 MG, 5 MG, 7.5 MG

Covered Uses

Afinitor is an oral tyrosine kinase inhibitor indicated to treat several malignancies.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

12 months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

everolimus (Zortress)

Drugs

Everolimus Oral Tablet 0.25 MG, 0.5 MG, 0.75 MG, 1 MG

Covered Uses

FDA approved indications. Patient must have failure or intolerance to a calcineurin inhibitor.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be a transplant specialist.

Coverage Duration

12 months

Other Criteria

Zortress is an immunosuppressive anti-rejection agent for solid organ transplant. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

evolocumab (Repatha)

Drugs

Repatha, Repatha Pushtronex System, Repatha SureClick

Covered Uses

Failure of rosuvastatin 40mg or atorvastatin 80 and ezetimibe 10mg in combination. Diagnosis of HeFH must be supported by Dutch Lipid Clinic Network criteria. Statin intolerant patients must have had a hydrophilic statin such as rosuvastatin, pravastatin, fluvastatin in the absence of fibrates or other combinations which can increase risk of myopathy or myalgia.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Repatha is a PCSK-9 inhibitor used to treat hypercholesterolemia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

fentanyl citrate lozenge (Actiq)

Drugs

fentaNYL Citrate Buccal Lozenge On A Handle

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Fentanyl citrate lozenges approved after failure of hydromorphone IR and morphine IR and oxycodone IR

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by an Oncologist or Pain Management through referrals.

Coverage Duration

12 months

Other Criteria

Fentanyl Citrate Lozenge is a short acting opioid indicated for cancer breakthrough pain. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

fentanyl transdermal product (Duragesic)

Drugs

Fentanyl Transdermal Patch 72 Hour 100 MCG/HR, 12 MCG/HR, 25 MCG/HR, 50 MCG/HR, 75 MCG/HR

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by an Oncologist or Pain Management through referrals.

Coverage Duration

12 months

Other Criteria

Fentanyl patch is a long acting opioid analgesic indicated for moderate to severe chronic pain. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

fidaxomicin (Difid)

Drugs

Difid Oral Tablet

Covered Uses

FDA approved indications. Failure of vancomycin 6 week taper dose (unless fulminant C-Difficile).

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

10days

Other Criteria

Difid is an oral antibiotic indicated to treat clostridium difficile related diarrhea. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

fingolimod (Gilenya)

Drugs

Fingolimod HCl

Covered Uses

Covered for patients who have failed a trial of glatiramer and Dimethyl Fumerate

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by a neurologist

Coverage Duration

12 months

Other Criteria

Gilenya is an oral medication indicated for treatment of relapsing remitting multiple sclerosis Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

frovatriptan (Frova)

Drugs

Frovatriptan Succinate

Covered Uses

FDA approved indications This medication requires failure of rizatriptan and sumatriptan prior to coverage.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Frova is a 5-HT_{1B/1D} agonist indicated for treatment of migraine headaches. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Drugs

Emgality, Emgality (300 MG Dose)

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Emgality is an anti-CGRP antibody indicated for prophylaxis of Episodic and Chronic Migraines, and Cluster Headaches. Episodic Migraines: Emgality 120 mg will be approved based upon all of the following criteria: (1) Diagnosis of episodic migraines with both of the following: (a) Less than 15 headache days per month (b) Patient has 4 to 14 migraine days per month - AND - (2) Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used: (a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol (e) Venlafaxine (Effexor/Effexor XR) - AND - (3) Medication will not be used in combination with an oral CGRP antagonist or inhibitor. Authorization will be issued for 6 months. B. Chronic Migraines: 1. Initial Therapy: Emgality 120 mg will be approved based upon all of the following criteria: (1) Diagnosis of chronic migraines with both of the following: (a) Greater than or equal to 15 headache days per month. Continued. (b) Greater than or equal to 8 migraine days per month - AND - Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used: (a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol (e) Venlafaxine (Effexor/Effexor XR) - AND - (3) Medication will not be used in combination with an oral CGRP antagonist. Authorization will be issued for 6 months. C. Episodic Cluster Headache: 1. Initial Therapy: a. Emgality 100 mg will be approved based upon all of the following criteria: (1) Diagnosis of episodic cluster headache - AND - (2) Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months. - AND - (3) Medication will not be used in combination with an oral CGRP antagonist. Authorization will be issued for 6 months.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

consultation with NEUROLOGY

Coverage Duration

See covered uses

Other Criteria

gefitinib (Iressa)

Drugs

Gefitinib

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. T790 mutation testing when indicated i.e. previously treated with a TKI inhibitor

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Oncologist

Coverage Duration

12 Months

Other Criteria

Iressa is indicated to treat non-small cell lung cancer with EGFR mutation exon 19 deletion or Exon 21 substitution mutations. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

glucagon (Baqsimi) nasal powder

Drugs

Baqsimi One Pack

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Ordered by an endocrinologist.

Coverage Duration

12 months

Other Criteria

Baqsimi is indicated for severe hypoglycemia where patient is unable to eat, drink or follow commands. Baqsimi is intranasal but does not need to be inhaled, patient does not need to be conscious for Baqsimi to be administered. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy. Limit of 1 device per dispensing, two per year.

golimumab (Simponi)

Drugs

Simponi Subcutaneous Solution Auto-Injector, Simponi Subcutaneous Solution Prefilled Syringe

Covered Uses

Covered only for Commercial/Exchange Simponi/is a TNF antagonist indicated for Moderate to severe rheumatoid arthritis, ankylosing spondylitis, active psoriatic arthritis, moderate to severe ulcerative colitis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows in Commercial and Exchange only: Must fail Hadlima and Renflexis

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

Hepatitis C Direct Acting Antivirals (DAA)

Drugs

Mavyret Oral Tablet, Zepatier

Covered Uses

FDA approved indications. Mavyret is the preferred DAA for all genotypes, other DAAs will be covered on a case by case basis if Mavyret use is not supported by current FDA indication or HCV guidelines based on patient specific characteristics.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Gastroenterologist or Infectious Disease

Coverage Duration

12 months

Other Criteria

Mavyret is the exclusive and preferred DAA for treatment of HCV in chronically infected non-cirrhotic and compensated cirrhotic patients for genotypes 1-6. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Humulin U-500

Drugs

Humulin R U-500 (Concentrated), Humulin R U-500 KwikPen Subcutaneous Solution Pen-Injector

Covered Uses

Initiation restricted to endocrinology. Insulin requirements of >200 units/day.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Initiation restricted to endocrinology.

Coverage Duration

12 months

Other Criteria

Humulin U 500 is used to treat insulin resistant diabetes mellitus. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

ibandronate (Boniva)

Drugs

Ibandronate Sodium Intravenous Solution 3 MG/3ML

Covered Uses

FDA approved indications. Failure of zoledronic acid.

Exclusion Criteria

Not for use in patients with severe renal impairment (CrCl;30 ml/min).

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Boniva IV is indicated for treatment of Osteoporosis. It is a parenteral bisphosphonate given by IV infusion every 3 months. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

ibrutinib (Imbruvica)

Drugs

Imbruvica Oral Capsule, Imbruvica Oral Tablet 420 MG, 560 MG

Covered Uses

FDA approved indications. NCCN supported use with evidence rating 2a or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Hematologist/oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Imbruvica is a BTK inhibitor used to treat B cell lymphomas. It is indicated for relapsed waldenstroms macroglobinemia, refractory chronic lymphocytic leukemia and Mantle Cell Lymphoma, and first line CLL. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

ibrutiniv (Imbruvica Sln)

Drugs

Imbruvica Oral Suspension

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Hematology/ Oncology/ Transplant Specialist

Coverage Duration

12 months

Other Criteria

Unable to swallow or use a tablet or capsule

icatibant (Firazyr)

Drugs

Icatibant Acetate Subcutaneous Solution

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Firazyr is indicated to treat acute attacks of Hereditary Angioedema Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Limited to two per month.

idelalisib (Zydelig)

Drugs **Zydelig**

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Zydelig is a PI3K kinase inhibitor for treatment of relapsed Chronic lymphocytic leukemia, relapsed follicular lymphoma, and small lymphocytic lymphoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

iloperidone (Fanapt)

Drugs

Fanapt, Fanapt Titration Pack

Covered Uses

FDA approved indications. Failure of aripiprazole, lurasidone.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Fanapt is indicated to treat schizophrenia. Prior authorization only applies to existing members who are new starts on the drug. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

iloprost (Ventavis)

Drugs **Ventavis**

Covered Uses

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization, Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral. Patient must be a WHO class III or IV and fail ambrisentan and tadalafil.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by a pulmonologist or cardiologist.

Coverage Duration

12 months

Other Criteria

Ventavis is a nebulized prostacyclin analog indicated to treat primary pulmonary arterial hypertension. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

incobotulinumtoxinA (Xeomin)

Drugs **Xeomin**

Covered Uses

FHCP covers this medication only for medically necessary purposes, like cervical dystonia, not responsive to physical therapy, blepharospasm that interferes significantly with vision, and headache not responsive to preventive and acute therapy by Neurology for at least 16 weeks.

Exclusion Criteria

FDA labeled contraindications OR cosmetic conditions

Required Medical Information

Medical notes, previous treatment history and associated studies

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

interferon beta-1a (Avonex)

Drugs

Avonex Pen Intramuscular Auto-Injector Kit, Avonex Prefilled Intramuscular Prefilled Syringe Kit

Covered Uses

Failure of glatiramer and Dimethyl Fumerate for new starts.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Avonex is an interferon indicated to treat multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

interferon beta-1a (Rebif)

Drugs

Rebif Rebidose Subcutaneous Solution Auto-Injector, Rebif Rebidose Titration Pack Subcutaneous Solution Auto-Injector, Rebif Subcutaneous Solution Prefilled Syringe, Rebif Titration Pack Subcutaneous Solution Prefilled Syringe

Covered Uses

Failure of glatiramer and Dimethyl Fumerate for new starts.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Rebif is an interferon indicated to treat multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

interferon beta-1b (Betaseron)

Drugs

Betaseron Subcutaneous Kit

Covered Uses

Failure of Dimethyl Fumarate and glatiramer or fingolimod for new starts

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Betaseron is an interferon indicated to treat multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Interferon gamma-1b (Actimmune)

Drugs

Actimmune

Covered Uses

FDA approved indications. Coverage will be based on medical history/status, antibiotic failure for chronic granulomatous disease.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Limited to specialist trained in management of prescribed condition.

Coverage Duration

Up to 12 months

Other Criteria

Actimmune is indicated to prevent infection in Chronic Granulomatous disease, and also delay the time to progression with severe malignant osteopetrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

ivacaftor (Kalydeco)

Drugs

Kalydeco Oral Packet 25 MG, 50 MG, 75 MG, Kalydeco Oral Tablet

Covered Uses

FDA approved indications. Patient must have an FDA approved mutation.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by a Pulmonologist.

Coverage Duration

12 months

Other Criteria

Kalydeco is an oral medication indicated to treat Cystic fibrosis patients with specific genetic mutations in the CFTR gene. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

ixazomib (Ninlaro)

Drugs **Ninlaro**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Must have failed bortezomib.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Oncology.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Ninlaro is an oral proteasome inhibitor indicated to treat relapsed or refractory multiple myeloma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

lacosamide (Vimpat)

Drugs

Lacosamide Oral Solution 10 MG/ML

Covered Uses

FDA approved indications. Failure of Levetiracetam, topiramate, and lamotrigine.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Neurologist.

Coverage Duration

12 months

Other Criteria

Vimpat is indicated as an adjunct agent used to treat partial onset seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Ianreotide (Somatuline)

Drugs

Somatuline Depot

Covered Uses

FDA approved indications. Failure of octreotide.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be an endocrinologist.

Coverage Duration

12 months

Other Criteria

This medication is used to treat Acromegaly. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

lanthanum carbonate (Fosrenol)

Drugs

Lanthanum Carbonate

Covered Uses

Patient has ESRD. Patient has elevated calcium on phosphate binders, or not a candidate for calcium based phosphate binders based on KDOQI guidelines. Failure of Sevelamer.

Exclusion Criteria

Not covered in combination with other non-calcium based phosphate binders.

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribed by a nephrologist.

Coverage Duration

12 months

Other Criteria

Fosrenol is a non-calcium based, chewable, phosphate binder indicated to manage hyperphosphatemia in ESRD. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

lapatinib (Tykerb)

Drugs

Lapatinib Ditosylate

Covered Uses

FDA approved indications. Patient has HER2/neu + breast cancer that has failed treatment/progressed with a regimen including an anthracycline, a taxane and Herceptin. Used to treat Metastatic HR+ HER2/neu+ breast cancer in combination with an aromatase inhibitor.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber is an oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Tykerb is indicated to treat Advanced HER2+ breast cancer in combination with Xeloda. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

lenalidomide (Revlimid)

Drugs

Lenalidomide

Covered Uses

FDA approved indications. Patient must have failed Aranesp & Procrit for MDS anemia. Mantle cell Lymphoma requires failure of two prior treatment regimens one of which being bortezomib.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber is a hematologist/oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Revlimid is indicated for treatment of Multiple Myeloma , Myelodysplastic syndrome, anemia that is transfusion dependent and has 5q deletion karyotype, mantle cell lymphoma Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

lenvatinib (Lenvima)

Drugs

Lenvima (10 MG Daily Dose), Lenvima (12 MG Daily Dose), Lenvima (14 MG Daily Dose), Lenvima (18 MG Daily Dose), Lenvima (20 MG Daily Dose), Lenvima (24 MG Daily Dose), Lenvima (4 MG Daily Dose), Lenvima (8 MG Daily Dose)

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by an oncologist/hematologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Lenvima is a tyrosine kinase inhibitor indicated for several cancers. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

levomilnacipran (Fetzima)

Drugs

Fetzima, Fetzima Titration

Covered Uses

FDA approved indications. Failure or intolerance to two generically available anti-depressants in past 6 months.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Fetzima is an antidepressant (enantiomer of milnacipran) used to treat major depressive disorder. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

liraglutide (Victoza)

Drugs

Liraglutide

Covered Uses

Covered after failure of metformin and Bydureon. Covered for use in established cardiovascular disease for patients on a Statin who have failed metformin.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Victoza is a medication indicated for treatment of type 2 diabetes mellitus.

macitentan (Opsumit)

Drugs **Opsumit**

Covered Uses

FDA approved indications. Failure of ambrisentan and sildenafil/tadalafil. Pulmonary hypertension diagnosed by right heart catheterization.

Exclusion Criteria

Required Medical Information

Medical notes, previous treatment history, and associated studies, including right heart catheterization.

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Opsumit is indicated for treatment Pulmonary arterial Hypertension (PAH). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

mecasermin (Increlex)

Drugs **Increlex**

Covered Uses

FDA approved indications. Coverage will be based on medical history/status, response to previous treatments, and the consideration of other therapeutic options.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by a Pediatric Endocrinologist.

Coverage Duration

12 months

Other Criteria

Increlex is indicated to treat short stature in patient with primary Insulin like Growth Factor deficiency, and patients with neutralizing antibodies to HGH. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

mepolizumab (Nucala)

Drugs Nucala

Covered Uses

The following criteria must be met for coverage for severe eosinophilic asthma: Prescriber must be a pulmonologist or allergist. Two or more severe exacerbations in the past 12 months. Patient must fail 3 months of therapy on maximal indicated doses of Trelegy and Montelukast.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Nucala is an interleukin 5 antagonist indicated for eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and nasal polyps. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Nasal Polyp indication is covered only by exception and will be based on all available treatment options including nebulized sinus treatments and devices.

midostaurin (Rydapt)

Drugs **Rydapt**

Covered Uses

FDA approved indications, off label use will be covered when used in alignment with NCCN recommendations of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by an oncologist/hematologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Rydapt is a kinase inhibitor indicated to treat AML, MCL, and systemic mastocytosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

miglustat (Zavesca)

Drugs

Miglustat

Covered Uses

FDA approved indications. Coverage will be based on medical history/status, response to previous treatments, and the consideration of other therapeutic options.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

Zavesca is indicated for treatment of non-neuropathic Gauchers disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

mipomersen (Kynamro)

Drugs

Kynamro Subcutaneous Solution Prefilled Syringe

Covered Uses

FDA approved indications. Genetic confirmation that patient is HoFH. Failure of Statin, Ezetimibe, and PCSK-9 therapy. Continuation of Kynamro after 3 month trial based on LDL reduction of at least 25% while on therapy.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

3 months initially, up to 12 months after response

Other Criteria

Kynamro is indicated to treat Homozygous Familial hypercholesterolemia Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

mirabegron (Myrbetriq)

Drugs

Mirabegron ER

Covered Uses

FDA approved indications. Failure of solifenacin, trospium, and Toviaz.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

This medication is used to treat over active bladder. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

molnupiravir (Lagevrio)

Drugs **Lagevrio**

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

nabilone (Cesamet)

Drugs **Cesamet**

Covered Uses

Failure of ondansetron AND palonosetron AND aprepitant

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Cesamet is a cannabinoid indicated to prevent nausea and vomiting related to chemotherapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

nafarelin acetate (Synarel)

Drugs **Synarel**

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written by an endocrinologist or gynecologist.

Coverage Duration

Up to 12 months

Other Criteria

Synarel is a GnRH analog (intranasal formulation) indicated to treat precocious puberty in children or endometriosis in adults. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

naloxegol (Movantik)

Drugs **Movantik**

Covered Uses

FDA approved indications. Requires failure of lactulose and Miralax.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Movantik is a Peripherally Acting Mu Opioid Antagonist (PAMORA) indicated for opioid induced constipation
Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

neratinib (Nerlynx)

Drugs **Nerlynx**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be a Hematologist/Oncologist

Coverage Duration

12 Months

Other Criteria

Nerlynx is indicated for extended adjuvant treatment of early stage HER2 breast cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

nicotine (Nicotrol)

Drugs Nicotrol

Covered Uses

Must have previously failed or have contraindication to Bupropion. Coverage is approved for 24 weeks of treatment. Copayment will be applied per package.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

24 weeks

Other Criteria

Indicated for smoking cessation therapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

nilotinib (Tasigna)

Drugs **Tasigna**

Covered Uses

FDA approved indications. Covered for treatment failure with imatinib.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Tasigna is an oral antineoplastic agent used to treat Philadelphia Chromosome + CML Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

niraparib (Zejula)

Drugs

Zejula Oral Capsule

Covered Uses

FDA approved indications, off label use will be covered when used in alignment with NCCN recommendations of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by an oncologist/hematologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Zejula is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

nisoldipine (Sular)

Drugs

Nisoldipine ER Oral Tablet Extended Release 24 Hour 17 MG, 25.5 MG, 34 MG, 8.5 MG

Covered Uses

FDA approved indications. Failure of Amlodipine and Diltiazem required for coverage of Nisoldipine, approved by referrals.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Nisoldipine is an oral calcium channel blocker used for treatment of hypertension Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

nitisinone (Orfadin)

Drugs

Nitisinone Oral Capsule 10 MG, 2 MG, 5 MG

Covered Uses

FDA approved indications. Failure of dietary modification.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by a specialist experienced in treatment of this disorder.

Coverage Duration

12 Months

Other Criteria

Orfadin is indicated for hereditary tyrosinemia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

ocrelizumab (Ocrevus)

Drugs **Ocrevus**

Covered Uses

FDA approved indications. For Relapsing Remitting Multiple Sclerosis must have failed Dimethyl Fumarate or Glatiramer

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by a neurologist.

Coverage Duration

12 months

Other Criteria

Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of relapsing remitting or primary progressive forms of multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

olanzapine (Zyprexa)

Drugs

Zyprexa Relprevv

Covered Uses

FDA approved indications. Failure of oral aripiprazole and olanzapine.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Psychiatrist or Neurologist through referrals for new starts.

Coverage Duration

12 months

Other Criteria

Zyprexa Relprevv is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

olaparib (Lynparza)

Drugs

Lynparza Oral Tablet

Covered Uses

Lynparza is used to treat BRCA+ ovarian or breast cancers.

Exclusion Criteria

Progression on a PARP inhibitor

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Restricted to Hematology/Oncology.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

omalizumab (Xolair)

Drugs

Xolair Subcutaneous Solution Prefilled Syringe 150 MG/ML, 75 MG/0.5ML, Xolair Subcutaneous Solution Reconstituted

Covered Uses

•Xolair is an anti-IgE monoclonal antibody indicated for patients 12 years and older with moderate to severe persistent asthma who have a positive skin test or in-vitro reactivity to an aeroallergen and chronic idiopathic urticaria. Xolair was not studied in patients who smoke. •Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. •Nasal Polyp indication is covered only by exception and will be based on all available treatment options including nebulized sinus treatments and devices The following criteria must be met for coverage for severe asthma:•Prescriber must be a pulmonologist or allergist. •Patient must have baseline IGE levels within indicated range for Xolair labeling. •Patient must test positive to an aeroallergen (either skin test or blood test). •Patient must fail 3 months of therapy on maximal indicated doses of Trelegy. •Patient must have failed leukotriene receptor antagonist The following criteria must be met for coverage for chronic idiopathic urticaria: •Prescribed by an allergist, immunologist, or dermatologist •Patient must have a diagnosis of chronic idiopathic urticaria (at least a 6 week history) •Patient must have tried, for a minimum of 2 weeks and failed 2 of the following antihistamines at maximal doses used to treat CIU: cetirizine(40mg/day), levocetirizine (20mg/day), desloratadine(20mg/day), fexofenadine (540mg/day), loratadine (40mg/day) with MONTELUKAST AND trial Dicyclomine or Hydroxyzine

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Omnipod/ Omnipod Dash

Drugs

Omnipod 5 DexG7G6 Intro Gen 5, Omnipod 5 DexG7G6 Pods Gen 5, Omnipod 5 G7 Intro (Gen 5), Omnipod 5 G7 Pods (Gen 5), Omnipod Classic Pods (Gen 3), Omnipod DASH Pods (Gen 4)

Covered Uses

Omnipod and Omnipod Dash are covered for Type 1 diabetics who meet MCG (Milliman Coverage Guideline) criteria

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician

onabotulinumtoxinA (Botox)

Drugs

Botox

Covered Uses

Non-Cosmetic FDA approved indications

Exclusion Criteria

FDA labeled contraindications, and excluded for cosmetic conditions

Required Medical Information

Medical notes, previous treatment history and associated studies

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

FHCP covers this medication only for medically necessary purposes, like cervical dystonia, not responsive to physical therapy, blepharospasm that interferes significantly with vision, and headache not responsive to preventive and acute therapy by Neurology for at least 16 weeks

osimertinib mesylate (Tagrisso)

Drugs **Tagrisso**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Must possess the t790m mutation if being used after progression on an EGFR tyrosine kinase inhibitor.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Tagrisso is indicated to treat patients with metastatic non-small cell lung cancer who possess an EGFR mutation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

oxandrolone (Oxandrin)

Drugs

Oxandrolone Oral

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written by Oncology, through referrals.

Coverage Duration

up to 12 months

Other Criteria

Oxandrin is an anabolic steroid indicated for weight gain in cachexia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

oxymetholone (Anadrol-50)

Drugs

Anadrol-50

Covered Uses

FDA approved indications. Medical history and information reviewed by referrals. Coverage will be response to previous treatments, and the consideration of other therapeutic options (ESAs, B12/folate, iron).

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

Anadrol is an anabolic steroid indicated to treat various types of anemia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

oxymorphone (Opana)

Drugs

Oxymorphone HCl ER

Covered Uses

For Chronic pain, failure of morphine sulfate ER, Methadone, and fentanyl patch. QTY limit of 93/month.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Oxymorphone is an opioid analgesic indicated for moderate to severe chronic pain. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

palbociclib (Ibrance)

Drugs **Ibrance**

Covered Uses

FDA approved indications. Diagnosis Metastatic ER+ HER- Breast cancer.

Exclusion Criteria

Progression on a CDK 4/6 inhibitor

Required Medical Information

Medical notes, previous treatment history and associated studies, including diagnosis of metastatic ER+ HER- breast cancer.

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Hematologist/oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Ibrance is a CDK 4/6 inhibitor indicated for first-line/second line treatment of metastatic ER+/HER- breast cancer used in combination with an aromatase inhibitor Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

paliperidone (Invega Sustenna) injection

Drugs

Invega Sustenna Intramuscular Suspension Prefilled Syringe

Covered Uses

FDA approved indications. Failure of oral aripiprazole, paliperidone and risperidone.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Psychiatrist or Neurologist through referrals.

Coverage Duration

12 months

Other Criteria

Invega Sustenna is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

panobinostat (Farydak)

Drugs **Farydak**

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be written by an oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Farydak is indicated to treat multiple myeloma in patients who have received at least two therapies including Velcade and an immunomodulatory agent. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

pazopanib (Votrient)

Drugs

PAZOPanib HCl

Covered Uses

Votrient is an oral tyrosine kinase inhibitor indicated to treat Renal cell carcinoma, and soft tissue sarcoma.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

12 months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

PegFilgrastim

Drugs

Fulphila, Udenyca, Udenyca Onbody

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

6 months

Other Criteria

All FDA approved uses, Off-Label uses must be NCCN supported with a grade 2a recommendation or greater.

peginterferon alfa-2b (Sylatron)

Drugs

Sylatron Subcutaneous Kit 200 MCG, 300 MCG, 600 MCG

Covered Uses

FDA approved indications. Must be used as adjuvant treatment within 84 days of surgical resection in patients with metastatic melanoma with nodal involvement.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be an oncologist.

Coverage Duration

Up to 12 months

Other Criteria

Sylatron is an adjuvant treatment for metastatic melanoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

penicillamine (Cuprimine)

Drugs

Penicillamine Oral Capsule

Covered Uses

FDA approved indications. Coverage for Rheumatoid Arthritis requires failure of a TNF Agent, and a JAK inhibitor or Abatacept.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Written by a Rheumatologist, or Neurologist, or Urologist or Hepatologist.

Coverage Duration

12 Months

Other Criteria

Cuprimine is indicated for treatment of Rheumatoid arthritis, Wilsons Disease and cystinuria. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

pentamidine isothionate (Nebupent) nebulized

Drugs

Pentamidine Isethionate Inhalation

Covered Uses

Failure of topical ketoconazole, econazole, clotrimazole betamethasone, nystatin triamcinolone.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Nebupent is a inhaled solution used to treat PCP pneumonia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

perampanel (Fycompa)

Drugs

Fycompa Oral Tablet

Covered Uses

Written by a neurologist for treatment of seizures. Failure of Levetiracetam, topiramate, and lamotrigine.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Written by a neurologist.

Coverage Duration

12 months

Other Criteria

Fycompa is an anti-convulsant indicated for adjunctive treatment of partial seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

phenoxybenzamine (Dibenzylamine)

Drugs

Phenoxybenzamine HCl Oral

Covered Uses

Diagnosis of Pheochromocytoma.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Dibenzylamine is used to treat pheochromocytoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

pirfenidone (Esbriet)

Drugs

Pirfenidone

Covered Uses

Pirfenidone is indicated for idiopathic pulmonary fibrosis. Medical history and studies are reviewed in Referrals and if approved will notify the physician. Criteria for coverage as follows: Confirmed diagnosis of IPF by high resolution CT or surgical biopsy. Prescribed by a pulmonologist

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

pulmonologist

Coverage Duration

12 months

Other Criteria

pomalidomide (Pomalyst)

Drugs **Pomalyst**

Covered Uses

FDA approved indications, Off label use must be supported by NCCN with evidence rating of 2a or greater. Coverage requires failure of Revlimid and Velcade.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Restricted to Hematology/Oncology.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Pomalyst is thalidomide analog used to treat refractory Multiple Myeloma Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

ponatinib (Iclusig)

Drugs **Iclusig**

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Must be prescribed by Hematologist/oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Iclusig is a tyrosine Kinase inhibitor indicated to treat Chronic Myelogenous Leukemia. Coverage will be based on failure of first or second line TKI for CML or presence of T350I mutation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

posaconazole (Noxafil)

Drugs

Noxafil Oral Suspension, Posaconazole Oral Tablet Delayed Release

Covered Uses

FDA approved indications. Organism must be resistant to itraconazole, voriconazole, and fluconazole.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

3 months

Other Criteria

Noxafil is an anti-fungal indicated for aspergillus and Candida in immunocompromised patients. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

pramlintide acetate (Symlin)

Drugs

SymlinPen 120 Subcutaneous Solution Pen-Injector, SymlinPen 60 Subcutaneous Solution Pen-Injector

Covered Uses

FDA approved indications. Patient is uncontrolled despite optimal insulin utilization with Ha1c between 7%-9%. Not for use in patients with gastroparesis.

Exclusion Criteria

Required Medical Information

Medical notes, previous treatment history, and labs, including HA1c

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber is an endocrinologist.

Coverage Duration

12 months

Other Criteria

Symlin is indicated to treat Type 1 and 2 Diabetes. Symlin is indicated for adjunctive treatment of DM with insulin. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

pyrimethamine (Daraprim)

Drugs

Pyrimethamine Oral

Covered Uses

Toxoplasmosis. Patient must have failed recent trial of combination of inhaled corticosteroids AND long acting beta Agonist AND inhaled anti-cholinergic.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 Months

Other Criteria

Daraprim is used to treat toxoplasmosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

regorafenib (Stivarga)

Drugs **Stivarga**

Covered Uses

Stivarga is an oral tyrosine kinase inhibitor indicated to treat Colorectal cancer and , Hepatocellular carcinoma.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

12 Months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

rilonacept (Arcalyst)

Drugs **Arcalyst**

Covered Uses

Diagnosis of CAPS and Documentation of disability due to the condition, failure of anakinra, and nsaid.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing limited to immunologist.

Coverage Duration

Up to 12 months

Other Criteria

Arcalyst is indicated to treat Cryopyrin Associated Periodic Syndromes (CAPS). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

riociguat (Adempas)

Drugs **Adempas**

Covered Uses

FDA approved indications. Failure of tadalafil and ambrisentan. Diagnosis of PAH supported by right heart catheterization. Failure of sildenafil and bosentan.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber must be a cardiologist or pulmonologist

Coverage Duration

12 months

Other Criteria

Adempas is indicated to treat Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTPH). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

risperidone (Risperdal Consta) injection

Drugs

risperidONE Microspheres ER

Covered Uses

FDA approved indications. Failure of oral aripiprazole and risperidone.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Psychiatrist or Neurologist through referrals.

Coverage Duration

12 months

Other Criteria

Risperdal Consta is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

rotigotine (Neupro)

Drugs **Neupro**

Covered Uses

FDA approved indications. Failure of Ropinirole and Pramipexole.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Neupro is a transdermal dopamine agonist indicated for treatment of Parkinsons disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

rufinamide (Banzel)

Drugs

Rufinamide

Covered Uses

FDA approved indications

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Approved when written/ordered by a Neurologist for seizures through referrals.

Coverage Duration

12 months

Other Criteria

Banzel is indicated for treatment of Lennox Gastaut syndrome. Prior authorization only applies to existing members who are new starts on the drug. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

ruxolitinib (Jakafi)

Drugs **Jakafi**

Covered Uses

FDA approved indications. Not used in combination with lenalidomide/thalidomide, other JAK or TKI inhibitors. Continuation in therapy will require 50% reduction in baseline spleen size, or 35% reduction in spleen volume, or a 50% reduction in baseline Myelofibrosis symptom score.

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescriber is a hematologist/oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Jakafi is an oral JAK inhibitor indicated for treatment of intermediate to high risk myelofibrosis including primary myelofibrosis, polycythemia vera, myelofibrosis, and essential thrombocythemia myelofibrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Drugs

Entresto Oral Tablet

Covered Uses

All FDA-approved indications not otherwise excluded from Part D. For Heart Failure with reduced ejection fraction (less than or equal to 40%) For initiation: eGFR greater than or equal to 30ml/min and K+ less than 5.0 meq/l for initiation Patient has NYHA Class II-IV symptoms Approve for 3 months initially For continuation: Member is at target dose approve for 12 months Member is below Entresto target dose THEN Approve for 3 months if member is tolerating dose but has not had a titration attempt and SBP greater than 100 OR Approve for 12 months if member has failed titration attempt or SBP less than 100 For Heart Failure with preserved ejection fraction For initiation: Patient has an ejection fraction less than or equal to 55% NYHA Class II-IV symptoms Currently taking an SGLT-2 inhibitor eGFR greater than 30 ml/min Approve for 3 months initially For continuation: Member is at target dose approve for 12 months Member is below Entresto target dose THEN Approve for 3 months if member is tolerating dose but has not had a titration attempt and SBP greater than 100 OR Approve for 12 months if member has failed titration attempt or SBP less than 100

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Entresto is a medication used for treatment of Heart Failure. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

sapropterin (Kuvan)

Drugs

Sapropterin Dihydrochloride

Covered Uses

FDA approved indications. Coverage will be based on medical history/status, response to previous treatments, Dietary compliance, and the consideration of other therapeutic options. PKU level above 6mg/dl (360 micromoles/L).

Exclusion Criteria

Required Medical Information

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Prescribing limited to specialist trained in management of PKU.

Coverage Duration

Up to 12 months

Other Criteria

Kuvan is indicated to treat Phenylketonuria (PKU). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sarilumab (Kevzara)

Drugs **Kevzara**

Covered Uses

Kevzara is an injectible Il-6 antagonist indicated for rheumatoid arthritis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: Coverage is limited to Rheumatoid arthritis. Must fail a preferred specialty agent (Enbrel, Xeljanz, Hadlima) Most have clear documentation of moderate to severe rheumatoid arthritis

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

sildenafil (Revatio)

Drugs

Sildenafil Citrate Oral Tablet 20 MG

Covered Uses

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization. Evaluation, EKG, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral.

Exclusion Criteria

This medication is contraindicated in patients using organic nitrates either regularly or intermittently

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Revatio is indicated for the treatment of Primary pulmonary hypertension or pulmonary hypertension related to connective tissue disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sitagliptin (Januvia)

Drugs **Januvia**

Covered Uses

FDA approved indications. Patient must be on maximal doses of Metformin and Sulfonylurea or other combination therapy if metformin contraindicated for at least 6 months, or have intolerance/contraindication. Failure of Onglyza.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Januvia is an oral anti-diabetic agent used to treat Type 2 Diabetes (DPP-IV inhibitor). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sodium oxybate (Xyrem)

Drugs

Sodium Oxybate

Covered Uses

Only covered for Narcolepsy with cataplexy. Coverage will be based on recent failure of Modafinil AND Armodafinil AND Amphetamine/Dextroamphetamine And soriamfetol. Tricyclic Antidepressant shown to be effective in cataplexy (Clomipramine/Protriptyline) and Venlafaxine (for cataplexy) Three month discontinuation trials for moderate to highly sedating medications such as benzodiazepines, opioids, anticholinergics, muscle relaxers, atypical antipsychotics, dopamine agonists.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be prescribed by physician board certified in sleep medicine.

Coverage Duration

Up to 12 months

Other Criteria

This medication is used for treatment of narcolepsy with cataplexy or excessive daytime sleepiness due to narcolepsy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sodium zirconium cyclosilicate (Lokelma)

Drugs

Lokelma

Covered Uses

Hyperkalemia after discontinuation trial of potassium sparing medications, trial of a loop diuretic if clinically indicated.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Lokelma is indicated for the treatment of hyperkalemia. Medical history and studies are reviewed in referrals and if approved will notify pharmacy and the physician.

somatropin (Omnitrope)

Drugs

Omnitrope Subcutaneous Solution Cartridge, Omnitrope Subcutaneous Solution Reconstituted

Covered Uses

FDA approved indications. This information with the lab attached is sent to the Referrals Department.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Growth Hormone is a pituitary hormone used for endogenous HGH deficiencies. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sonidegib (Odomzo)

Drugs **Odomzo**

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be prescribed by Oncology.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Odomzo is an oral oncology agent indicated to treat locally advanced basal cell carcinoma which has recurred following radiation or surgery. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sorafenib (Nexavar)

Drugs

SORafenib Tosylate

Covered Uses

Nexavar is an oral tyrosine kinase inhibitor indicated to treat Renal cell carcinoma, Hepatocellular carcinoma, and thyroid carcinoma.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

12 months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sucroferric oxyhydroxide (Velphoro)

Drugs **Velphoro**

Covered Uses

Patient has ESRD. Patient has e calcium on phosphate binders, or not a candidate for calcium based phosphate binders based on KDOQI guidelines.

Exclusion Criteria

Not covered in combination with other non-calcium based phosphate binders.

Required Medical Information

Age Restriction

Prescriber Restriction

Prescribed by a nephrologist

Coverage Duration

Up to 12 months

Other Criteria

Velphoro is a non-calcium based phosphate binder indicated to manage hyperphosphatemia in ESRD. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sulconazole (Exelderm)

Drugs

Exelderm External Cream, Exelderm External Solution

Covered Uses

FDA approved indications. Patient has failed 2 generically available topical anti-fungals in past 6 months. Approved by referrals based on pharmacy history.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Exelderm is a topical antifungal indicated for tinea pedis tinea corporis, and tinea versicolor. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

sunitinib (Sutent)

Drugs

SUNItinib Malate

Covered Uses

Sutent is an oral tyrosine kinase inhibitor indicated to treat Renal cell carcinoma, Gastrointestinal Stromal Tumors, and pancreatic neuroendocrine tumors.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Prescribing restricted to oncology.

Coverage Duration

12 Months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Sunosi

Drugs

Sunosi Oral Tablet 150 MG, 75 MG

Covered Uses

Sunosi is a dopamine and norepinephrine inhibitor indicated for treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea. Coverage is limited to indication of Narcolepsy Criteria for coverage as follows: Failure of Modafinil and Armodafinil

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Board Certified Sleep Medicine

Coverage Duration

12 months

Other Criteria

tadalafil (Adcirca)

Drugs

Tadalafil (PAH)

Covered Uses

FDA approved indications. Pulmonary hypertension must be diagnosed by right heart catheterization. Evaluation, EKG, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral.

Exclusion Criteria

This medication is contraindicated in patients using organic nitrates either regularly or intermittently.

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Adcirca is indicated for treatment of pulmonary arterial hypertension (WHO group 1). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tapentadol (Nucynta)

Drugs **Nucynta ER**

Covered Uses

FDA approved indications. For Chronic pain, failure of morphine sulfate, tramadol, and fentanyl patch. For DPN must fail an oral opioid and duloxetine.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Nucynta is an opioid analgesic indicated for chronic pain or severe diabetic peripheral neuropathy (DPN). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tazarotene (Tazorac)

Drugs

Tazarotene External Cream 0.1 %, Tazarotene External Gel, **Tazorac External Cream 0.05 %**

Covered Uses

FDA approved indications. For Psoriasis patient must have failed medium to high potency topical corticosteroid. For acne patient must have failed adapalene or tretinoin or oral tetracycline class antibiotic.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be written by dermatology.

Coverage Duration

12 months

Other Criteria

Tazorac is a topical retinoid indicated to treat Acne or Psoriasis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

telbivudine (Tyzeka)

Drugs **Tyzeka**

Covered Uses

FDA approved indications. Coverage will be based on medical history/status, response to previous treatments, and the consideration of other therapeutic options.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Tyzeka is indicated for chronic hepatitis B infection. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Teriflunomide

Drugs

Teriflunomide

Covered Uses

Teriflunimide is indicated to treat Multiple Sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. Prescriber must be a neurologist.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

teriparatide (Forteo)

Drugs

Teriparatide Subcutaneous Solution Pen-Injector 620 MCG/2.48ML

Covered Uses

FDA approved indications.

Exclusion Criteria

FDA labeled contraindications. Exclusions also include use in children, adolescents, Paget's patients with Paget's disease or hypercalcemia, or patients with a history of primary or metastatic bone cancer.

Required Medical Information

Medical notes, previous treatment history and associated studies, including BMD, Vit D, Calcium, and iPTH.

Age Restriction

Ages approved in FDA labeling/compendia

Prescriber Restriction

Coverage Duration

12 months, but limited to total treatment duration of 2 years.

Other Criteria

Patient must be diagnosed with osteoporosis with a BMD less than -2.5. Patient must have failed treatment with IV bisphosphonate and denosumab. For Patients with calculated GFR or CRcl ; 60ml/min, referral must include recent iPTH. Vitamin D (25 OH, 1,25 OH) must be within normal limits.

tetrabenazine (Xenazine)

Drugs

Tetrabenazine

Covered Uses

FDA approved indications. Patient must have moderate to severe chorea that is refractory to amantadine, neuroleptics or anticonvulsants.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Prescriber must be a neurologist.

Coverage Duration

12 months

Other Criteria

Xenazine is indicated to treat chorea associated with Huntingtons disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tetrahydrocannabinol (Marinol)

Drugs

Dronabinol

Covered Uses

For cachexia, patient must fail megestrol acetate. For nausea and vomiting patient must fail Ondansetron and Emend.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Dronabinol is indicated to treat HIV/Cancer related Cachexia and chemotherapy induced nausea and vomiting. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

thalidomide (Thalomid)

Drugs

Thalomid

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Approved when written by Oncology, Infectious Disease or in HIV through referrals.

Coverage Duration

12 months

Other Criteria

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tipiracil / trifluridine (Lonsurf)

Drugs **Lonsurf**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be prescribed by an Oncologist

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Lonsurf is indicated to treat patients with metastatic colorectal cancer who have progressed on two to three lines of treatment. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tofacitinib (Xeljanz)

Drugs

Xeljanz Oral Solution, Xeljanz Oral Tablet, Xeljanz XR

Covered Uses

FDA approved indications. For rheumatoid arthritis must be written by Rheumatology, Patient must fail adequate trial of MTX in combination with a DMARD If MTX contraindicated, must try combination of 2- nonbiologic DMARDS (3 month trial in past 6 months) and a preferred TNF. For Psoriatic Arthritis Patient must fail adequate trial of MTX or LEF in past 6 months. For with ulcerative colitis must be written by a gastroenterologist and had recent failure of an immunosuppressant (Azathioprine, 6-mp or Methotrexate) and an anti-inflammatory (5-asa, sulfasalazine, balsalazide, mesalamine)

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

For rheumatoid arthritis must be written by Rheumatology. For with ulcerative colitis must be written by a gastroenterologist.

Coverage Duration

Up to 12 months

Other Criteria

Xeljanz is indicated for treatment of Moderate to severe Rheumatoid arthritis in adults, Psoriatic Arthritis, Ulcerative colitis, JIA. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tolcapone (Tasmar)

Drugs

Tolcapone

Covered Uses

FDA approved indications. Failure of carbidopa/levo depo, entacapone, ropinirole, pramipexole, selegiline and amantadine.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be written by a neurologist.

Coverage Duration

12 months

Other Criteria

Tasmar is indicated for adjunctive treatment of Parkinsons disease when used adjunctively with levo-dopa and carbidopa. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tramadol (Ultram)

Drugs

Tramadol HCl ER

Covered Uses

FDA approved indications. Approved after failure of tramadol IR.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Tramadol ER is an opioid analgesic Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

trametinib (Mekinist)

Drugs

Mekinist Oral Tablet

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Patient must have BRAF V600E/K mutation.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be written by an oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Mekinist is a MEK inhibitor indicated to treat BRAF+ V600e/k mutation Stage IIIc-IV metastatic Melanoma and NSCLC. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

treprostinil (Orenitram)

Drugs

Orenitram

Covered Uses

Group 1 PAH. Right Heart catheterization to diagnose PAH. Failure of combination ERA+PDE5 inhibitor, failure of remodulin

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be prescribed by a Pulmonologist or Cardiologist.

Coverage Duration

12 Months

Other Criteria

Orenitram is indicated to treat Pulmonary Arterial Hypertension. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tretinoin ()

Drugs

Tretinoin Oral

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Approved when written by Oncology through referrals.

Coverage Duration

12 months

Other Criteria

Vesanoid is indicated to treat promyelocytic leukemia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

tretinoin (Retin-A)

Drugs

Tretinoin External Cream, Tretinoin External Gel 0.01 %, 0.025 %

Covered Uses

Tretinoin is indicated to treat moderate to severe acne and diseases of keratinization such as ichthyosis and keratosis follicularis. Prior authorization only required for patients greater than 30 years of age. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. This medication is not covered for wrinkles or photo aging.

Exclusion Criteria

This medication is not covered for wrinkles or photo aging.

Required Medical Information

Age Restriction

Prior authorization only required for patients greater than 30 years of age.

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

ustekinumab (Stelara)

Drugs

Stelara Subcutaneous Solution 45 MG/0.5ML, Stelara Subcutaneous Solution Prefilled Syringe

Covered Uses

Stelara is indicated for treatment of moderate to severe plaque psoriasis and psoriatic arthritis and Crohn's disease. Medical history and studies are reviewed in Referrals and if approved will notify the physician. Criteria for coverage as follows: •FDA approved indications only at FDA approved doses •Prescribed by a dermatologist or Rheumatologist. •Only covered as a medical benefit. •Notes supporting moderate to severe Plaque psoriasis or Psoriatic arthritis •For Plaque Psoriasis, recent failure (in past 6 months) of Renflexis, and Enbrel in combination with topical treatment following conventional therapy. •For Psoriatic Arthritis failure of adalimumab, Renflexis, Enbrel, Xeljanz,. •For Crohns Disease must fail conventional agents AND adalimumab, Renflexis, Entyvio, , AND TNF in combination with a conventional immunosuppressant (when clinically appropriate) with 5-ASA anti-inflammatory. •For Ulcerative Colitis must fail conventional agents AND adalimumab, Renflexis, Entyvio, Xeljanz, AND TNF in combination with a conventional immunosuppressant (when clinically appropriate) with 5-ASA anti-inflammatory.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Up to 12 months

Other Criteria

vandetanib (Caprelsa)

Drugs Caprelsa

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Prescriber must be a Hematologist/Oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Caprelsa medication indicated for treatment of metastatic medullary thyroid cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

vemurafenib (Zelboraf)

Drugs **Zelboraf**

Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Patient must have BRAF V600E/K mutation.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be written by an oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Zelboraf is a BRAF inhibitor indicated to treat BRAF+ V600e/k mutation Stage IIIc-IV metastatic Melanoma, NSCLC, and Metastatic colorectal cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

venetoclax (Venclexta)

Drugs

Venclexta, Venclexta Starting Pack

Covered Uses

FDA approved indications.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Restricted to Hematology/Oncology.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Venclexta is a BCL-2 inhibitor indicated for treatment BCell Lymphomas. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

vismodegib (Erivedge)

Drugs **Erivedge**

Covered Uses

FDA approved indications. Patient has Metastatic basal cell cancer, or recurrent basal cell cancer, or who are not candidates for surgery and not candidates for radiation.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Prescriber is a hematologist/oncologist.

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Erivedge is indicated for treatment of metastatic or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and are not candidates for radiation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

voriconazole (Vfend)

Drugs

Voriconazole Oral

Covered Uses

FDA approved indications. Two of the following medications have been tried, unless resistance or contraindication precludes use, Itraconazole, fluconazole, ketoconazole. Exclusions to pre-requisite medications are Invasive pulmonary aspergillosis, Scedosporium apiospermum, and fusarium.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Voriconazole is an antifungal medication used to treat aspergillosis and other invasive fungal infections. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

vorinostat (Zolinza)

Drugs **Zolinza**

Covered Uses

FDA approved indications. Failed minimum of two systemic treatments, one of which must be Targretin, unless contraindicated.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Up to 12 months or until disease progression or toxicity

Other Criteria

Zolinza is indicated for cutaneous manifestations of cutaneous T-cell Lymphoma Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

vortioxetine (Trintellix)

Drugs **Trintellix**

Covered Uses

FDA approved indications. Failure or intolerance to two generically available anti-depressants in past 6 months.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Trintellix is an antidepressant used to treat major depressive disorder. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

zileuton (Zyflo)

Drugs

Zileuton ER

Covered Uses

FDA approved indications. Uncontrolled Asthma while on maximal doses of long acting bronchodilators and inhaled corticosteroids AND montelukast. 6 months of medication compliance with maintenance treatments.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Must be written by a pulmonologist.

Coverage Duration

12 months

Other Criteria

Zyflo is indicated for treatment of asthma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

Index		
Abilify Maintena Intramuscular Prefilled Syringe	12	
Abiraterone Acetate Oral Tablet 250 MG.....	2	
Actimmune	79	
Adempas	135	
Aimovig	48	
Alecensa	6	
Almotriptan Malate.....	8	
Ambrisentan.....	9	
Anadrol-50	115	
Aprepitant Oral Capsule.....	11	
Aptiom	51	
Arcalyst	134	
Avonex Pen Intramuscular Auto-Injector Kit	76	
Avonex Prefilled Intramuscular Prefilled Syringe Kit	76	
Baqsimi One Pack	64	
Benefix Intravenous Kit	17	
Berinert	20	
Betaseron Subcutaneous Kit	78	
Bosentan.....	18	
Bosulif Oral Tablet	19	
Botox	112	
Caprelsa	172	
Carglumic Acid Oral Tablet Soluble.....	22	
Cayston	15	
Cesamet	98	
Cinacalcet HCl.....	24	
Clobazam.....	25	
Cometriq (100 MG Daily Dose) Oral Kit 80 & 20 MG	21	
Cometriq (140 MG Daily Dose) Oral Kit 3 x 20 MG & 80 MG	21	
Cometriq (60 MG Daily Dose)	21	
Cotellic	26	
Dalfampridine ER.....	29	
Dasatinib.....	30	
Deferasirox Oral Tablet Soluble..	31	
Deferiprone.....	32	
Dificid Oral Tablet	59	
Dimethyl Fumarate Oral.....	36	
Dimethyl Fumarate Starter Pack Oral.....	36	
Doxepin HCl External.....	39	
Doxepin HCl Oral Tablet.....	38	
Dronabinol.....	161	
Emend Oral Suspension Reconstituted	11	
Emgality	62	
Emgality (300 MG Dose)	62	
Enbrel Mini	53	
Enbrel Subcutaneous Solution 25 MG/0.5ML	53	
Enbrel Subcutaneous Solution Prefilled Syringe	53	
Enbrel Subcutaneous Solution Reconstituted	53	
Enbrel SureClick Subcutaneous Solution Auto-Injector	53	
Entresto Oral Tablet	140	
Ergomar	49	
Erivedge	175	
Erlotinib HCl.....	50	
Everolimus Oral Tablet 0.25 MG, 0.5 MG, 0.75 MG, 1 MG.....	55	
Everolimus Oral Tablet 2.5 MG, 5 MG, 7.5 MG.....	54	
Exelderm External Cream	151	
Exelderm External Solution	151	
Fanapt	73	
Fanapt Titration Pack	73	
Farydak	119	
fentaNYL Citrate Buccal Lozenge On A Handle.....	57	
Fentanyl Transdermal Patch 72 Hour 100 MCG/HR, 12 MCG/HR, 25 MCG/HR, 50 MCG/HR, 75 MCG/HR.....	58	
Fetzima	88	
Fetzima Titration	88	
Fingolimod HCl.....	60	
Firmagon.....	33	
Frovatriptan Succinate.....	61	
Fulphila	121	
Fycompa Oral Tablet	125	
Gefitinib.....	63	
Gilotrif	5	
Hadlima	4	
Hadlima PushTouch	4	
Humulin R U-500 (Concentrated)	67	
Humulin R U-500 KwikPen Subcutaneous Solution Pen-Injector	67	
Ibandronate Sodium Intravenous Solution 3 MG/3ML.....	68	
Ibrance	117	
Icatibant Acetate Subcutaneous Solution.....	71	
Iclusig	129	
Idhifa	44	
Imbruvica Oral Capsule	69	
Imbruvica Oral Suspension	70	
Imbruvica Oral Tablet 420 MG, 560 MG	69	
Increlex	91	
Inlyta	14	
Invega Sustenna Intramuscular Suspension Prefilled Syringe	118	
Jakafi	139	
Januvia	144	
Kalydeco Oral Packet 25 MG, 50 MG, 75 MG	80	
Kalydeco Oral Tablet	80	
Kevzara	142	
Kineret Subcutaneous Solution Prefilled Syringe	10	
Kynamro Subcutaneous Solution Prefilled Syringe	95	
Lacosamide Oral Solution 10 MG/ML.....	82	
Lagevrio	97	
Lanthanum Carbonate.....	84	
Lapatinib Ditosylate.....	85	
Lenalidomide.....	86	
Lenvima (10 MG Daily Dose)	87	
Lenvima (12 MG Daily Dose)	87	
Lenvima (14 MG Daily Dose)	87	
Lenvima (18 MG Daily Dose)	87	
Lenvima (20 MG Daily Dose)	87	
Lenvima (24 MG Daily Dose)	87	
Lenvima (4 MG Daily Dose)	87	
Lenvima (8 MG Daily Dose)	87	
Liraglutide.....	89	
Lokelma	146	
Lonsurf	163	
Lynparza Oral Tablet	109	
Mavyret Oral Tablet	66	

Mekinist Oral Tablet	167	Posaconazole Oral Tablet		Strensiq	13
Menest Oral Tablet 0.3 MG,		Delayed Release.....	130	SUNItinib Malate.....	152
0.625 MG, 1.25 MG	52	Prolia Subcutaneous Solution		Sunosi Oral Tablet 150 MG, 75	
Miglustat.....	94	Prefilled Syringe	34	MG	153
Mirabegron ER.....	96	Promacta Oral Packet 12.5 MG.	43	Sylatron Subcutaneous Kit 200	
Movantik	100	Promacta Oral Tablet	43	MCG, 300 MCG, 600 MCG	122
Multaq	40	Pulmozyme Inhalation Solution		SymlinPen 120 Subcutaneous	
Nerlynx	101	2.5 MG/2.5ML	37	Solution Pen-Injector	131
Neupro	137	Pyrimethamine Oral.....	132	SymlinPen 60 Subcutaneous	
Nicotrol	102	Qvar RediHaler Inhalation		Solution Pen-Injector	131
Ninlaro	81	Aerosol Breath Activated 40		Synarel	99
Nisoldipine ER Oral Tablet		MCG/ACT, 80 MCG/ACT	16	Tadalafil (PAH).....	154
Extended Release 24 Hour 17		Rebif Rebidose Subcutaneous		Tafinlar Oral Capsule	28
MG, 25.5 MG, 34 MG, 8.5 MG..	105	Solution Auto-Injector	77	Tagrisso	113
Nitisinone Oral Capsule 10 MG,		Rebif Rebidose Titration Pack		Tasigna	103
2 MG, 5 MG.....	106	Subcutaneous Solution Auto-		Tazarotene External Cream 0.1	
Noxafil Oral Suspension	130	Injector	77	%.....	156
Nucala	92	Rebif Subcutaneous Solution		Tazarotene External Gel.....	156
Nucynta ER	155	Prefilled Syringe	77	Tazorac External Cream 0.05 %	156
Nuedexta	35	Rebif Titration Pack		Teriflunomide.....	158
Ocrevus	107	Subcutaneous Solution		Teriparatide Subcutaneous	
Odomzo	148	Prefilled Syringe	77	Solution Pen-Injector 620	
Omnipod 5 DexG7G6 Intro Gen		Repatha	56	MCG/2.48ML.....	159
5	111	Repatha Pushtrex System	56	Tetrabenazine.....	160
Omnipod 5 DexG7G6 Pods Gen		Repatha SureClick	56	Thalomid	162
5	111	Retacrit Injection Solution		Tolcapone.....	165
Omnipod 5 G7 Intro (Gen 5)	111	10000 UNIT/ML, 2000		Tramadol HCl ER.....	166
Omnipod 5 G7 Pods (Gen 5)	111	UNIT/ML, 20000 UNIT/ML,		Tretinoin External Cream.....	170
Omnipod Classic Pods (Gen 3) ..	111	3000 UNIT/ML, 4000 UNIT/ML,		Tretinoin External Gel 0.01 %,	
Omnipod DASH Pods (Gen 4) ...111		40000 UNIT/ML	47	0.025 %.....	170
Omnitrope Subcutaneous		risperiDONE Microspheres ER..	136	Tretinoin Oral.....	169
Solution Cartridge	147	Rozlytrek Oral Capsule	45	Trintellix	178
Omnitrope Subcutaneous		Rufinamide.....	138	Tyzeka	157
Solution Reconstituted	147	Rydapt	93	Udenyca	121
Opsumit	90	Sapropterin Dihydrochloride....	141	Udenyca Onbody	121
Orencia Intravenous	1	Sildenafil Citrate Oral Tablet 20		Velphoro	150
Orenitram	168	MG.....	143	Venclexta	174
Oriahnn	42	Simponi Subcutaneous		Venclexta Starting Pack	174
Orilissa	41	Solution Auto-Injector	65	Ventavis	74
Oxandrolone Oral.....	114	Simponi Subcutaneous		Voriconazole Oral.....	176
Oxymorphone HCl ER.....	116	Solution Prefilled Syringe	65	Xalkori Oral Capsule	27
Panretin	7	Sodium Oxybate.....	145	Xartemis XR	3
PAZOPanib HCl.....	120	Somatuline Depot	83	Xeljanz Oral Solution	164
Penicillamine Oral Capsule.....	123	SORafenib Tosylate.....	149	Xeljanz Oral Tablet	164
Pentamidine Isethionate		Stelara Subcutaneous Solution		Xeljanz XR	164
Inhalation.....	124	45 MG/0.5ML	171	Xeomin	75
Phenoxybenzamine HCl Oral....	126	Stelara Subcutaneous Solution		Xolair Subcutaneous Solution	
Pirfenidone.....	127	Prefilled Syringe	171	Prefilled Syringe 150 MG/ML,	
Pomalyst	128	Stivarga	133	75 MG/0.5ML	110

Xolair Subcutaneous Solution

Reconstituted	110
Xtandi	46
Zejula Oral Capsule	104
Zelboraf	173
Zepatier	66
Zileuton ER	179
Zolinza	177
Zydelig	72
Zykadia Oral Tablet	23
Zyprexa Relprevv	108